OBJECTIVE The aim is to observe the effects of argatroban injection and butylphthalide injection on blood flow rheology, clinical efficacy, and safety in patients with acute cerebral infarction. METHODS 344 patients with acute cerebral infarction within 48 h after admission were divided into treatment group and control group, with 172 cases in each group. The control group received routine treatment. The treatment group received argatroban injection 60 mg on the basis of the control group, intravenously guttae (ivgtt) was used for 2 days and then changed to argatroban injection 10 mg, ivgtt bid for 5 days, and the total course of treatment was 7 days. The neurological changes, activities of daily living, and the rheology indicators (fibrinogen [Fib], platelet aggregation rate [Pag], whole blood high shear viscosity [Whsv], hematocrit [Hct]) were compared between the 2 groups, clinical efficacy and adverse drug reactions. RESULTS After treatment, the total effective rates of the treatment group and the control group were 90.70% (156 /172 cases) and 74.41% (128 and 172 cases), respectively, and the difference was statistically significant (p < 0.05). After treatment, the National Institutes of Health Stroke Scale scores of the treatment group and the control group were (7.05 ± 1.97) and (8.30 ± 1.79), respectively, and the Barthel index was (68.02 ± 11.07) and (62.32 ± 11.46), respectively. The difference was statistically significant (p < 0.05). After treatment, the treatment group and the control group were (2.66 ± 0.22) g/L and (3.50 ± 0.22) g/L, respectively, and Pag were (0.68 ± 0.06)% and (0.81 ± 0.09)%, respectively, and Whsv was (6.44 ± 0.76) mPs/s and (6.87 ± 0.91) mPs/s, Hct were (8.19 ± 1.21)% and (10.44 ± 1.04)%, respectively, and the differences were statistically significant (p < 0.05). The incidence of adverse reactions in the treatment group and the control group was 6.97 and 5.81%, respectively, and the difference was not statistically significant (p > 0.05). CONCLUSION Argatroban injection is effective in the treatment of acute cerebral infarction, which can significantly improve the hemorheology of patients with good safety.

中文翻译：

---

阿加曲班注射液对急性脑梗死患者临床疗效的影响：初步结果

目的观察阿加曲班注射液和丁苯酞注射液对急性脑梗死患者血流流变学、临床疗效及安全性的影响。方法将入院后48 h内发生急性脑梗死的344例患者分为治疗组和对照组，每组172例。对照组接受常规治疗。治疗组在对照组基础上给予阿加曲班注射液60mg，静脉滴注牙胶（ivgtt）2天后改为阿加曲班注射液10mg，ivgtt bid，共5天，总疗程为7天。 . 神经系统变化、日常生活活动和流变学指标（纤维蛋白原 [Fib]、血小板聚集率 [Pag]、全血高剪切粘度 [Whsv]、比较两组患者的血细胞比容[Hct]、临床疗效和药物不良反应。结果治疗后治疗组和对照组总有效率分别为90.70%（156例/172例）和74.41%（128例和172例），差异有统计学意义（p<0.05）。治疗后，治疗组和对照组的美国国立卫生研究院卒中量表评分分别为（7.05±1.97）和（8.30±1.79），Barthel指数分别为（68.02±11.07）和（62.32±11.46） ， 分别。差异具有统计学意义（p < 0.05）。治疗后，治疗组和对照组分别为（2.66±0.22）g/L和（3.50±0.22）g/L，Pag分别为（0.68±0.06）%和（0.81±0.09）%， Whsv 为 (6.44 ± 0. 76) mPs/s 和 (6.87 ± 0.91) mPs/s, Hct 分别为 (8.19 ± 1.21)% 和 (10.44 ± 1.04)%, 差异有统计学意义 (p < 0.05)。治疗组和对照组不良反应发生率分别为6.97%和5.81%，差异无统计学意义（p>0.05）。结论阿加曲班注射液治疗急性脑梗死疗效显着，可显着改善患者的血液流变学，安全性较好。